Dr. Tartakover Matalon holds a doctorate in Immunology from the Haifa School of Medicine, Technion, Israel. Upon completion of her Ph.D., she had two years of postdoctoral training in the Center for Autoimmune Diseases at Sheba Medical Center in the field of Autoimmunity and Pregnancy. For the next 15 years, Dr. Matalon was a chief researcher in the Oncogenic laboratory at Meir Hospital in the field of Cancer and Pregnancy. In 2020, Shelly became the new manager of the autoimmune research laboratory, which belongs to the internal medicine E department at Meir Medical Center. The laboratory focuses on pathologies where the immune system of the subject attacks its own body components, such as systemic sclerosis (a disease of connective tissue). Research is conducted in several areas with the aim of promoting personalized medicine: 1) Discovering markers (glycosylated proteins, young cells, autoantibodies, miRNA) for evaluation and diagnosis of rare autoimmune diseases. 2) Understanding mechanisms underlying disease progression in order to find new therapeutic targets and exploring the effectivity and mechanisms of action of new therapies for autoimmune diseases. Dr. Tartakover Matalon is a Senior Lecturer at the Sackler Faculty of Medicine at Tel-Aviv University in Israel, and has published more than 45 articles and two chapters in books.
Dr. Tartakover Matalon holds a doctorate in Immunology from the Haifa School of Medicine, Technion, Israel. Upon completion of her Ph.D., she had two years of postdoctoral training in the Center for Autoimmune Diseases at Sheba Medical Center in the field of Autoimmunity and Pregnancy. For the next 15 years, Dr. Matalon was a chief researcher in the Oncogenic laboratory at Meir Hospital in the field of Cancer and Pregnancy. In 2020, Shelly became the new manager of the autoimmune research laboratory, which belongs to the internal medicine E department at Meir Medical Center. The laboratory focuses on pathologies where the immune system of the subject attacks its own body components, such as systemic sclerosis (a disease of connective tissue). Research is conducted in several areas with the aim of promoting personalized medicine: 1) Discovering markers (glycosylated proteins, young cells, autoantibodies, miRNA) for evaluation and diagnosis of rare autoimmune diseases. 2) Understanding mechanisms underlying disease progression in order to find new therapeutic targets and exploring the effectivity and mechanisms of action of new therapies for autoimmune diseases. Dr. Tartakover Matalon is a Senior Lecturer at the Sackler Faculty of Medicine at Tel-Aviv University in Israel, and has published more than 45 articles and two chapters in books.